Valpro

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valpro

Quick Facts

Property Description
Active ingredient Valproic Acid, Sodium Valproate, Divalproex Sodium
Form Tablets, Capsules, Syrup, Injection
Pharmacological class Anticonvulsant, Mood Stabilizer
General Purpose Systemic regulation of nerve cell activity
Origin Synthetic Compound (Carboxylic Acid Derivative)

What Type of Medicine is Valpro and What is its Composition?

The medicine known as Valpro is a prescription-only drug classified as a Central Nervous System (CNS) Agent, clinically recognized as both an Anticonvulsant (Antiepileptic Drug, AED) and a potent Mood Stabilizer. The core active chemical substance is Valproic Acid (VPA), a synthetic compound that is a Carboxylic Acid Derivative. Its chemical identity is 2-propylpentanoic acid. Formulations often use derivative salts, specifically Sodium Valproate or the stable coordination compound Divalproex Sodium, which are all converted to the active valproate ion in the body. Valproate is used as an antiepileptic medicine due to its ability to control seizure activity and stabilize sudden, excessive electrical disturbances in the brain.


What are the Available Forms and General Therapeutic Purpose?

Valproic Acid is manufactured in several distinct dosage forms to accommodate various patient needs, including oral tablets (often as extended-release preparations), oral capsules, liquid oral syrup (solution), and a preparation for intravenous injection (IV solution). These forms permit delivery via the oral or parenteral route of administration. The medicine's general therapeutic purpose is to act as a systemic regulator that promotes steadier, more predictable brain function. Valproic Acid works by increasing concentrations of the inhibitory neurotransmitter GABA, which is a key mechanism for dampening neuronal excitability. The availability of syrup and specialized extended-release tablets ensures flexibility, particularly for pediatric patients requiring liquid dosing or for adults needing consistent delivery throughout the day.

What side effects are possible with Valpro?

Possible Side Effects and Safety Information

The official safety profile of Valproate is defined by the categorization of potential adverse reactions based on their frequency and the system-organ class affected, as established in regulatory documents like the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).


Adverse Reaction Frequencies and Systems

Adverse effects are documented across various systems and are classified by official frequency standards:

Classification Examples of Adverse Reactions (SOC)
Very Common (1/10) Nervous System (Tremor); Gastrointestinal (Nausea)
Common (1/100 to < 1/10) Metabolism (Weight gain); Blood (Thrombocytopenia); Nervous System (Somnolence)

Nausea and gastrointestinal effects are frequently reported at the beginning of treatment. Certain effects, such as a potential decrease in bone mineral density (osteopenia), are associated with long-term use.


Serious Adverse Reactions and Safety Constraints

The medicine carries explicit, serious risks defined in regulatory labeling. These include potentially fatal conditions such as Hepatic Failure (liver injury) and Pancreatitis, which are often highlighted with specific warnings. Additionally, Valproate is associated with a class-wide risk of Suicidal Ideation and Behavior among antiepileptic drugs.

Specific Population-Specific Safety Considerations are detailed, including heightened risks for certain groups. The medicine is contraindicated in patients with known severe hepatic impairment or a diagnosed urea cycle disorder. Furthermore, due to high risks of major congenital malformations and neurodevelopmental problems, Valproate has strict limitations for women of childbearing potential, particularly when used for migraine prophylaxis.

Overdose and Emergency Response

Overdose Manifestations and Severity

Valproate overdose is officially documented as potentially life-threatening, primarily presenting as progressive Central Nervous System (CNS) depression. Initial signs may include drowsiness, lethargy, and ataxia, which can advance rapidly to profound coma and respiratory depression. Severe toxicity is associated with systemic metabolic derangements, including hyperammonemia, elevated anion gap metabolic acidosis, and potential cerebral edema. Officially documented severe outcomes include multi-organ system toxicity, circulatory collapse, and fatal outcomes have been reported in cases of severe poisoning.


When to Seek Help and Required Actions

Immediate medical evaluation is strictly mandated for any suspected overdose due to the potential for rapid progression of life-threatening symptoms. Hospital monitoring and extended observation are required, particularly for patients who have ingested extended-release formulations, as peak toxicity may be delayed. Management is officially described as symptomatic and supportive. While no specific antidote is known, official protocols may include procedures such as administering activated charcoal, gastric lavage, or utilizing enhanced elimination techniques like hemodialysis for massive ingestions. Regulatory labeling notes that elderly patients are more susceptible to somnolence, and children under two face a considerably increased risk of fatal hepatotoxicity.

Therapeutic Uses of Valpro

Valpro may assist with symptoms related to systemic imbalance and is commonly used to help with conditions where functional stability becomes affected. Typically, the medication is applied across three main therapeutic domains: is used for managing various forms of epilepsy and seizure disorders; is relevant for easing acute and chronic mood swings associated with bipolar disorder; and contributes to prophylactic relief from recurrent migraines.


Key Therapeutic Applications

This medication is generally used for managing conditions involving recurrent or episodic manifestations and is applied to help ease the symptom burden of recurrent episodes of symptoms of increased neurological activity. Valproate is considered relevant as symptomatic support in treating the acute symptoms of manic episodes and for long-term management. In the context of bipolar disorder, it contributes to easing the overall symptom load by managing manifestations like severe irritability, racing thoughts, and impulsivity. The drug may be applied in situations requiring support against chronic pain recurrence:

“The approach supports general well-being during symptomatic phases and may help patients cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Episodic Instability

Property Description
Epilepsy Focus Is used for managing multiple seizure types, including generalized tonic-clonic and absence seizures.
Mood Focus Supports acute manic episodes and is used for managing long-term maintenance of bipolar disorder.
Prophylaxis Focus Contributes to easing the frequency in recurrent, debilitating migraine headaches.
Patient Benefit Provides support that helps ease the overall symptom burden and assists with maintaining functional stability.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Valpro — Official Regulatory Information

Populations That Must Not Use Valpro

Valpro is contraindicated and must not be used by patients with:

  • Significant hepatic dysfunction or pre-existing liver disease.
  • Known urea cycle disorders (UCDs), due to the risk of fatal hyperammonemic encephalopathy.
  • Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG), or a suspected POLG-related disorder in children under two years of age.
  • Known hypersensitivity to the drug.

Use in Women and Girls of Childbearing Potential

Valpro is contraindicated for women and girls of childbearing potential unless all conditions of a special Pregnancy Prevention Programme (PPP) are met. This includes receiving an independent specialist assessment and using effective contraception. The drug is also contraindicated for the prevention of migraine headaches during pregnancy.

Age-Related Eligibility

The medicine is generally indicated for adults and pediatric patients 10 years of age or older for certain seizure types. Use in children under two years of age is strongly discouraged due to a significantly increased risk of fatal liver toxicity. Safety and efficacy for certain uses are not established for children under 10.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Valpro (valproic acid/valproate) has documented interactions with numerous medications, primarily stemming from its effects on hepatic enzymes and protein binding.

Clinically Significant Interaction Classes

The following domains define the official interaction profile and necessitate careful patient monitoring or dosage adjustments:

Interaction Domain Practical Implication
Hepatic Enzyme-Inducing Antiepileptic Drugs (e.g., Phenytoin, Carbamazepine) These drugs can increase Valproate clearance, potentially reducing its effectiveness. Valproate concentration monitoring is required when initiating or discontinuing these agents.
Other Antiepileptic Drugs (e.g., Lamotrigine, Ethosuximide) Valproate can inhibit the metabolism of these drugs, significantly increasing their plasma levels, which often necessitates reducing the co-administered drug's dose.
Carbapenem Antibiotics (e.g., Meropenem, Ertapenem) These antibiotics cause a rapid and substantial decrease in Valproate concentrations, potentially leading to loss of seizure control. Co-administration is generally restricted.
Drugs Affecting Hemostasis (e.g., Warfarin, Aspirin) Combining Valproate, which can affect platelet function, with anticoagulants or salicylates increases the risk of bleeding. Coagulation parameters must be closely monitored.

Other Notable Interactions

Topiramate co-administration is associated with an increased risk of hyperammonemia with or without encephalopathy. Medications with CNS depressant effects, such as alcohol or benzodiazepines, may lead to additive sedation when combined with Valproate. Conversely, Rifampin may decrease Valproate concentrations by inducing liver enzymes.

Mechanism of Action

How Valpro Works

Valproate's function is driven by three main, simultaneous biological actions that collectively influence central nervous system ( CNS) excitability by decreasing the capacity for excessive electrical signaling.


1. Reinforcing the Inhibitory Neurotransmission System

The drug reinforces the intrinsic inhibitory system by targeting the GABAergic pathway. It acts as an inhibitor of the enzyme GABA Transaminase ( GABA-T), which metabolizes the inhibitory neurotransmitter GABA, resulting in sustained higher concentrations of GABA at the synapse. This core mechanism results in a systemic decrease in neuronal firing frequency, reflecting a shift in the chemical balance toward inhibitory control.


2. Modulating Electrically Active Membranes

Valproate directly influences nerve cell responsiveness by modulating key ion channels. It blocks specific Voltage-Gated Sodium Channels ( Na^+), particularly those engaged during high-frequency firing, and inhibits T-type Calcium Channels ( Ca^2+). This restricts the cell's ability to propagate rapid, high-frequency electrical signals, leading to the maintenance of the membrane's resting potential and a decrease in the wide-scale propagation of nerve impulses.


3. Influencing Long-Term Neuronal Adaptability

In addition to its immediate effects on channels and neurotransmitters, Valproate engages in slower, epigenetic regulation. It inhibits Histone Deacetylases ( HDACs), which alters the expression of various genes involved in neuronal adaptation and survival. This action influences the long-term function and adaptability of neurons, extending beyond immediate control of electrical activity.

Dosage and Administration Information

How to Use Valpro

Valproic Acid, Divalproex Sodium, and Sodium Valproate formulations are used according to established protocols concerning route, dosage, and administration schedule. The medication is primarily intended for oral administration for long-term use. The intravenous (IV) route is used as a temporary substitute when oral intake is not feasible, with use typically restricted to a maximum of 14 days.

Dosage and Frequency

Treatment initiation begins with a low daily dose, such as 10 to 15 mg/kg/day for seizure management. The daily dosage is then progressively increased at weekly intervals until the required maintenance dose is achieved, generally not to exceed 60 mg/kg/day. Dosage frequency depends on the specific formulation: immediate or delayed-release tablets require divided daily doses, while extended-release tablets are formulated for once-daily administration.

Administration Requirements

Oral preparations may be taken with food to mitigate gastrointestinal irritation. A critical procedural condition is that extended-release and delayed-release tablets must be swallowed whole and must not be crushed, broken, or chewed. Conversely, the contents of sprinkle capsules may be mixed with a small amount of soft food, such as applesauce, and must be consumed immediately.

Population and Procedural Adjustments

Clinical protocols indicate that older adults begin with a reduced starting dose and undergo a slower rate of dosage adjustment. Dosing requires specialized management for patients with hepatic or renal impairment. In the event a dose is missed, standard practice suggests it should be taken as soon as possible, but it is advised not to double the subsequent dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Valpro


Evidence for Use in Epilepsy and Seizure Disorders

This section will summarize the structure of clinical research, including randomized controlled trials (RCTs) and meta-analyses, that contributed to the regulatory evaluation of the medicine for use in various seizure types, such as complex partial and absence seizures, in both adult and pediatric populations.

Research has extensively explored Valpro's use relevant in trials assessing short-term or episodic symptom patterns in different forms of seizures. Short-term RCTs and trials examined how symptoms change over time by monitoring the frequency of seizure events and the proportion of participants achieving seizure freedom. Studies monitored adults with newly diagnosed and chronic epilepsy, as well as pediatric patients for certain seizure types. In these studies conducted during periods of increased symptom activity, the findings describe patterns observed in the studies. Specifically, studies observed measured changes in the frequency of complex partial seizures compared to control measurements. The body of evidence is large, but results apply only to the populations studied.


Evidence for Use in Acute Manic and Mixed Episodes

Valpro was evaluated in numerous short-term (3 to 4 week) RCTs focusing on acute episodes of manic or mixed episodes associated with Bipolar Disorder in adults. Studies explored how symptoms evolved in the observed populations by using standardized Mania Rating Scales to measure outcomes related to systemic or functional imbalance. Studies conducted during periods of heightened symptom activity consistently reported a greater magnitude of change in Mania Rating Scale scores in the Valpro-treated groups compared to the control groups over the short observation intervals. These findings are aligned with the medicine's regulatory position for acute episode management.


Evidence for Use in Migraine Prophylaxis

Randomized, placebo-controlled trials applied in research contexts involving fluctuating or unstable symptoms were conducted to assess Valpro's use in preventing migraine headaches in adults. Studies monitored outcomes related to physical discomfort by measuring the reduction in the average number of monthly migraine headaches and the related use of acute pain medication over observation periods typically lasting about three to four months. Findings describe patterns observed in the studies that show a reduction in monthly headache frequency compared to placebo measurements in the observed populations. This research highlights what is known for prevention and does not address the treatment of an already active migraine attack.


What is Still Uncertain About Valpro Research

One consistent gap is the limited information for long-term outcomes and the durability of response across all indications, as most definitive trials were short-to-intermediate in duration. The evidence base also shows varying quality and consistency when exploring outcomes for the depressive phase of Bipolar Disorder. Data for certain special groups, such as older adults, remain insufficient, meaning certainty remains low in these areas. The research provides context but not individual predictions.

Key Studies & References The efficacy of valproate in acute mania, bipolar depression and maintenance therapy for bipolar disorder: an overview of systematic reviews

Frequently Asked Questions (FAQ)

Common questions about Valpro (FAQ)


Q: Can Valpro cause weight changes?

Official product information indicates that weight gain is a common adverse reaction reported during clinical trials. Changes in appetite are also listed as common side effects. If you have concerns about weight changes, discussing them with a healthcare provider is appropriate.


Q: Are dizziness or drowsiness common side effects when starting Valpro?

Yes, dizziness and somnolence (drowsiness) are both listed as common adverse reactions in the official drug label. These effects are often reported by patients at the beginning of treatment. If these side effects become bothersome, seeking guidance from a healthcare professional is recommended.


Q: Can Valpro affect my sleep?

Regulatory documents state that Valproate is associated with effects on sleep. Both somnolence (drowsiness) and insomnia (difficulty sleeping) are reported as adverse reactions. These effects are classified as common in the official product information.


Q: Is it normal to have stomach upset when starting Valpro?

Nausea, vomiting, and other gastrointestinal effects are categorized as very common adverse reactions associated with Valproate. These side effects are frequently reported when beginning treatment. Official guidance suggests that taking the medication with food may help to mitigate gastrointestinal issues.


Q: Is Valpro a blood thinner?

Valproate is not classified as a blood thinner, but it can affect the way your body’s platelets function, which are cells essential for clotting. Due to this effect, monitoring is often necessary, especially when combined with other medications that affect hemostasis.


Q: Are there any foods to avoid while taking Valpro?

Regulatory documents instruct that Valproate can be taken with food to help reduce stomach or digestive irritation. The official patient information does not list specific foods that must be avoided, but official regulatory guidance advises limiting or avoiding alcohol consumption due to the increased risk of drowsiness and dizziness.


Q: Does Valpro interact with birth control pills?

Official drug labels state that taking Valproate with estrogen-containing hormonal contraceptives may decrease the concentration of Valproate in the body. When co-administered, monitoring of valproate levels and potential dosage adjustment may be necessary.


Q: Is it safe to drink alcohol while taking Valpro?

Alcohol is a central nervous system (CNS) depressant and can intensify Valproate’s side effects, such as dizziness, drowsiness, and difficulty concentrating. Official patient information recommends avoiding or limiting alcohol consumption due to the potential for increased CNS effects.


Q: How long does Valpro typically stay in your system?

The time it takes for Valproate to be eliminated from the body is measured by its half-life, which is approximately 9 to 16 hours in adults using it alone. However, this can vary widely depending on the individual and whether they are taking other interacting medications.


Q: Does Valpro have a risk of dependence or withdrawal if stopped suddenly?

Regulatory guidance strongly advises against the sudden discontinuation of Valproate. Sudden discontinuation can increase the risk of withdrawal symptoms and may potentially lead to a higher frequency of seizure events.


Q: What are the long-term side effects of taking Valpro?

Some severe adverse reactions, such as pancreatitis (inflammation of the pancreas), can potentially occur even after several years of use. Long-term use is also associated with effects like a possible decrease in bone mineral density. Regular medical monitoring is important when using this medication for extended periods.


Q: Does Valpro cause hair loss?

Yes, alopecia, which is the medical term for hair loss, is listed as a common adverse reaction associated with the use of Valproate. This is detailed in the official list of documented side effects.


Q: Will Valpro make me feel tired all the time?

Somnolence (drowsiness) is a common side effect of Valproate. Additionally, asthenia (weakness or lack of energy) is a frequently reported adverse reaction. If you feel excessively tired, discussing this with a healthcare professional is advisable.


Q: Are there any vitamins or supplements that interact with Valpro?

While regulatory labels primarily detail prescription drug interactions, it is important for patients to discuss all vitamins, herbal products, and supplements with their healthcare provider. This is necessary because potential interactions may exist with various substances.


Q: Can Valpro be taken with common pain relievers like ibuprofen?

Caution is advised when combining Valproate with certain pain relievers like high-dose ibuprofen. This is because ibuprofen can sometimes increase the concentration of Valproate in the bloodstream. Due to this potential interaction, monitoring may be required.


Q: What kind of regular monitoring is required while on Valpro?

Regular testing and monitoring are typically required for patients taking Valproate to monitor for potential risks. Serum liver tests should be performed prior to therapy and at frequent intervals, especially during the first six months. Platelet counts and coagulation tests are also generally recommended.


Q: Does Valpro affect fertility in men or women?

Official information reports that Valproate has been linked to infertility in men, which may improve if the drug is discontinued. In women, the medication can also cause changes to the menstrual cycle. This information is found in regulatory product summaries.


Q: Can Valpro cause mood swings or irritability?

As part of a class-wide warning for antiepileptic drugs, patients are advised to be monitored for new or worsening symptoms. This includes changes in mood and behavior such as agitation, irritability, and anxiety.


Q: Is there a generic version of Valpro available?

Yes, the active ingredient, Valproic Acid and its derivatives, is available in various generic formulations approved by regulatory authorities. These generic options are available in addition to the different brand name products.


Q: How often do people need to adjust their dosage of Valpro?

Initially, the dosage is progressively increased at weekly intervals until a required maintenance dose is achieved. Further dosage adjustments may be necessary if other interacting medications are added or withdrawn from the regimen.


Q: What should I do if I think I'm having an allergic reaction to Valpro?

Valproate is associated with severe reactions like DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms). If you experience signs of a severe reaction, such as a fever, rash, or swollen glands, you should seek medical attention immediately.


Q: Can Valpro affect my concentration at work or school?

Yes, official labeling includes reports of thinking abnormalities and amnesia as adverse reactions. Furthermore, patients are cautioned that the medicine may cause drowsiness, which can impair the ability to perform tasks requiring complete mental alertness.


Q: Does food change how Valpro is absorbed?

Clinical pharmacology data suggests that while the rate at which Valproate is absorbed may be affected by taking it with food, the overall extent of absorption (bioavailability) is generally not altered. It is still recommended to take it with food to reduce stomach irritation.


Q: Is it okay to take Valpro with my antidepressant?

Valproate is often used concurrently with other psychiatric medications. However, because some antidepressants have CNS depressant effects, combining them with Valproate could lead to increased sedation. The decision to combine these medications is made by a healthcare professional after careful evaluation.


Q: Does Valpro interfere with diagnostic lab tests?

Yes, Valproate can interfere with certain diagnostic tests. Specifically, it has been reported to cause a false interpretation of the urine ketone test and may also alter the results of some thyroid function tests.


Q: Is Valpro known by any other brand names?

The active ingredient, Valproic Acid and its derivative Divalproex Sodium, is sold under several well-known brand names. These include, but are not limited to, Depakene and Depakote, depending on the specific formulation.


Q: How long does it take for Valpro to reach a stable level in the body?

The time required to reach a stable concentration in the bloodstream, known as 'steady state,' is variable. Given the necessary gradual increase in dosage over several weeks, it can take anywhere from a few days to several weeks to achieve stable, therapeutic levels, which are confirmed by blood tests.


Q: What happens if I take Valpro too close to bedtime?

As Valproate is associated with the common side effect of somnolence (drowsiness), taking the medication too close to bedtime may potentially increase feelings of fatigue or sedation, which is a known CNS effect.

How should Valpro be stored and disposed of?

Storage and Disposal Instructions for Valproate Products

Valproate products must be stored and handled according to regulatory requirements to ensure stability and safety.

Official Storage Conditions

Oral tablets and capsules must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container and the container must remain tightly closed. Liquid forms, such as oral solution, have the mandatory instruction: Do not freeze. For safety, all forms of valproate must be kept out of the sight and reach of children.

Disposal

Unused or expired medication should be disposed of via an official drug take-back program. If this is unavailable, the product must be mixed with an undesirable substance in a sealed container for household trash disposal. Disposal into wastewater, such as flushing down a toilet or sink, is prohibited.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valpro found in:

A-Z Index: